PubMed Health⌕ Search

Biomedical subjects

Brian M Sullivan

Publications and source records attributed to Brian M Sullivan.

3 recordsLinked to original sources

Combinatorial augmentation for a multi-pathogen biosensor: signal analysis and design.

Recent advances in combinatorial chemistries have revolutionized approaches to drug candidate synthesis and screening. Combinatorial approaches are also beginning to be used to increase the performance of diagnostic devices for both clinical and field uses. The use of combinatorial technologies is motivated by a general desire to detect as many different pathogens using the smallest, most inexpensive and fastest system possible. We examine the potential for rational design approaches to enhance the performance and miniaturization of biosensors. We describe novel combinatorial biosensor systems, in addition to mathematical frameworks for their optimization and performance prediction. The biosensors are assumed to be composed of multiple detection channels with the following characteristics. Each channel has a single output and can be dynamically set to respond to some or all of a set of pathogens. Regardless of the number of pathogens detected, however, there is a single numerical output from a channel. We evaluate the amount of ambiguity of positive signals produced as a result of increasing both the number of channels and the number of pathogens detected per channel and the effect this ambiguity has on system performance. We further discuss strategies for disambiguating positive signals. Finally we cite specific biosensor configurations that exploit the findings above and compare them to "brute force" approaches. Overall we suggest the approach we refer to as "n-squared" to simultaneously optimize device cost, speed and reagent usage.

Algorithms↗

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. PRO 542 binds to the viral surface glycoprotein gp120 and blocks attachment and entry of virus into CD4(+) cells. Previously, PRO 542 demonstrated antiviral activity without significant toxicity when tested at single doses ranging to 10 mg/kg. In this study, 12 HIV-infected individuals were treated with 25-mg/kg single-dose PRO 542 and then monitored for safety, antiviral effects, and PRO 542 pharmacokinetics for 6 weeks. The study examined two treatment cohorts that differed in the extent of HIV-1 disease progression. PRO 542 at 25 mg/kg was well tolerated and demonstrated a serum half-life of 3 days. Statistically significant acute reductions in HIV-1 RNA levels were observed across all study patients, and greater antiviral effects were observed in the cohort of patients with more advanced HIV-1 disease. In advanced disease (HIV-1 RNA > 100,000 copies/ml; CD4 lymphocytes < 200 cells/mm(3)), PRO 542 mediated an 80% response rate and statistically significant approximately 0.5 log(10) mean reductions in viral load for 4 to 6 weeks posttreatment. Similar findings were obtained in an analysis of all (n = 11) advanced disease patients treated to date with single doses of PRO 542 ranging from 1 to 25 mg/kg. In addition, a significant correlation was observed between antiviral effects observed in vivo and viral susceptibility to PRO 542 in vitro. The findings support continued development of PRO 542 for salvage therapy of advanced HIV-1 disease.

Adult↗

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Inhibitors of human immunodeficiency virus type 1 attachment (CD4-immunoglobulin G subclass 2), CCR5 usage (PRO 140), and fusion (T-20) were tested on diverse primary cell types that represent the major targets both for infection in vivo and for the inhibition of trans infection of target cells by virus bound to dendritic cells. Although minor cell-type-dependent differences in potency were observed, each inhibitor was active on each cell type and trans infection was similarly vulnerable to inhibition at each stage of the fusion cascade.

Anti-HIV Agents↗